Regulus Therapeutics Inc. announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development. Dr. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. Dr. Preston Klassen is an established nephrologist who brings years of experience in leadership, medical affairs, and research and development across multiple therapeutic areas.

Most recently he served as the President and CEO of Metacrine. Prior to that, he was an Executive Vice President and Head of R&D at Arena Pharmaceuticals, CMO and President at SANIFIT, and Senior Vice President and Head of Global Development at Orexigen Therapeutics. Previously, while at Amgen, he held multiple leadership roles, including Executive Medical Director and Therapeutics Area Head for Nephrology.

Dr. Klassen earned his M.D. from the University of Nebraska Medical Center and completed both his residency in internal medicine and nephrology as well as his Master's in Health Sciences at Duke University Medical Center.